5,099 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by CSM Advisors LLC

CSM Advisors LLC bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,099 shares of the specialty pharmaceutical company’s stock, valued at approximately $541,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Philip James Wealth Mangement LLC raised its holdings in Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after buying an additional 4,675 shares during the period. State of Alaska Department of Revenue increased its position in shares of Jazz Pharmaceuticals by 75.1% in the second quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock worth $6,147,000 after acquiring an additional 24,850 shares in the last quarter. Inspire Investing LLC purchased a new position in shares of Jazz Pharmaceuticals in the first quarter worth approximately $689,000. Baird Financial Group Inc. acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $539,000. Finally, Voya Investment Management LLC lifted its position in shares of Jazz Pharmaceuticals by 67.1% in the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock valued at $6,996,000 after acquiring an additional 22,628 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $133.19 on Tuesday. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The stock’s 50-day moving average is $133.32 and its two-hundred day moving average is $119.69. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The firm has a market cap of $8.09 billion, a P/E ratio of -19.79, a PEG ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.54 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on JAZZ. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Truist Financial upped their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Morgan Stanley set a $183.00 price objective on Jazz Pharmaceuticals in a research report on Friday, October 24th. JPMorgan Chase & Co. dropped their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Finally, Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.50.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 11,500 shares of company stock worth $1,525,280. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.